Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018, St. Jude Children's Research Hospital
St. Jude investigators (from left) Michael Rusch, Sheila Shurtleff, Ph.D., Jinghui Zhang, Ph.D., and Scott Newman, Ph.D. Credit: St. Jude Children's Research Hospital

St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings appeared online recently in the scientific journal Nature Communications.

Researchers showed that incorporating into clinical genomic testing led to identifying additional cancer-driving mutations in almost half of patients in a recent study. These mutations could not be identified by sequencing just the protein-coding regions of the genome (exome) and gene expression (transcriptome).

The pilot study included 78 children and adolescents with a wide variety of cancers who were treated at St. Jude and had undergone extensive diagnostic testing. The research laid the foundation for the clinical genomic testing now offered to every new St. Jude cancer patient. The effort included developing a clinical pipeline for analyzing, validating and identifying clinically significant results in a timely manner.

"This research offers a new gold standard for clinical genomic testing and emphasizes the critical need for incorporating whole-genome sequencing into clinical testing and treatment of pediatric cancer patients," said James R. Downing, M.D., St. Jude president and chief executive officer. Downing; Jinghui Zhang, Ph.D., chair of the St. Jude Department of Computational Biology; and David Ellison, M.D., Ph.D., chair of the St. Jude Department of Pathology, are the study's corresponding authors.

Whole-genome sequencing involves determining the exact order of the 3 billion chemical bases that make up human DNA, the molecule that encodes the instructions for assembling and sustaining life. Although whole-genome sequencing offers the most comprehensive assessment of differences between patients' normal and cancer genomes, the method is not in widespread clinical use, in part due to cost and timeliness of results.

Currently, clinical testing with next-generation sequencing often involves integrated analysis of more limited sequencing of the whole exome and whole transcriptome, also known as RNA sequencing. The exome is the 1 to 2 percent of the genome that encodes instructions for assembling proteins. The transcriptome identifies genes that are being expressed.

Findings

This study compared results of clinical tests that integrated whole-genome and whole-exome sequencing of patients' tumors and normal DNA plus the whole transcriptome of tumor DNA, with results when the analysis was limited to the exome and transcriptome. The testing was done in a CLIA-certified and CAP-accredited St. Jude clinical diagnostic laboratory.

For 47 percent of patients, clinical tests that included whole-genome sequencing identified known or likely cancer-causing mutations that were not picked up in tests with just whole exome and whole transcriptome sequencing.

Testing that included all three next-generation sequencing methods detected 99 percent of known or suspected cancer-causing mutations compared to 78 percent of mutations from tests with whole exome and whole transcriptome alone.

"This really showed the value of whole-genome sequencing, at least for childhood cancer," Zhang said.

The genomic alterations that give rise to and fuel cancer vary widely. Cancer mutations include single base changes (point mutations) in the genetic code, structural variations caused by chromosomal rearrangements and deletion or addition of DNA segments. "Different sequencing methods are better for identifying different alterations," Zhang said, adding that whole-genome sequencing is the best approach for finding certain mutations that are widely seen in childhood cancer. "It is not surprising that incorporating whole-genome sequencing in the analysis discovered high-risk mutations that or whole-transcriptome sequencing did not," she said.

Ellison added, "We expect the combined sequencing methods to provide a comprehensive view of the genetic alterations in a child's cancer that matter most for treatment decisions and also to serve as a discovery engine for the genetic basis of uncommon childhood cancers."

The study builds on the St. Jude—Washington University Pediatric Cancer Genome Project. Launched in 2010, the Pediatric Cancer Genome Project sequenced the normal and genomes of more than 800 young patients with some of the least understood and most aggressive cancers. The project has produced groundbreaking discoveries in a number of cancers as well as computational algorithms that have improved genomic sequencing analysis.

For this study, researchers developed an analytic pipeline to detect, compare and validate variations in tumor and germline DNA identified in whole genome, exome and transcriptome sequencing. Likely or suspected pathogenic variants were identified. The rankings and clinical importance were then reviewed by a committee of experts with bioinformatics, genetic and clinical expertise before the findings were reported to clinicians and included in patient medical records.

Today the pipeline provides reported results in an average of 31 days. That is comparable to the turnaround time for returning results of tumor exome sequencing or similar genomic testing. Per patient costs of sequencing and storing whole genome, exome and transcriptome data have declined since the study began in 2013.

A key feature of the clinical pipeline was software developed by co-first author Michael Rusch of the St. Jude Computational Biology Department and his colleagues. The pipeline streamlined integration and validation of genomic variants picked up by the different sequencing platforms. "Validating the results across all three sequencing platforms improved the accuracy and sensitivity of the results," Rusch said.

Sequenced data used in this study, both raw and processed, are available to researchers worldwide via the St. Jude PeCan (pediatric cancer) data portal in St. Jude Cloud. St. Jude researchers hope the access will fuel future research and development or clinical applications involving whole-genome sequencing.

Explore further: Blood cancer patients benefit from breakthrough genetic testing service

Related Stories

Blood cancer patients benefit from breakthrough genetic testing service

August 27, 2018
Cutting-edge DNA sequencing technology has been used by QUT researchers at the new Australian Translational Genomics Centre (ATGC) to identify genetic mutations in 100 patients with blood cancers, with this testing providing ...

Genomic analysis underscores need for precision therapies that target pediatric cancer

February 28, 2018
Researchers have determined that children and adults with cancer usually have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative ...

Clinical exome sequencing useful for critically ill infants

October 3, 2017
(HealthDay)—Clinical exome sequencing is an effective diagnostic tool for infants suspected of having monogenic disorders, according to a study published online Oct. 2 in JAMA Pediatrics.

New study suggests more than 8 percent of children with cancer have genetic predisposition

November 18, 2015
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all ...

Genetic counseling and testing proposed for patients with the brain tumor medulloblastoma

May 9, 2018
Researchers have identified six genes that predispose carriers to develop the brain tumor medulloblastoma and have used the discovery to craft genetic counseling and screening guidelines. The study appears today in the journal ...

Blood mutations could contaminate genetic analyses of tumors

June 5, 2018
Genetic mutations in blood cells that have made their way into tumors could be red herrings that mislead physicians looking for genetic changes in tumors that are helping to drive the cancer. This finding is significant because ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Receiving genetic information can change risk

December 11, 2018
Millions of people in the United States alone have submitted their DNA for analysis and received information that not only predicts their risk for disease but, it turns out, in some cases might also have influenced that risk, ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

How glial cells develop in the brain from neural precursor cells

December 11, 2018
Two types of cells are active in the brain: nerve cells and glial cells. Glial cells have long been regarded primarily as supportive cells, but researchers increasingly recognize that they play an active role in the communication ...

Breast cancer drug could create chink in the armour of pancreatic cancer

December 11, 2018
The well-known drug tamoxifen could exploit a weakness in the physical 'scaffolds' around tumours, according to research led by Imperial.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.